ストックスクリーナーアプリを入手
1.57
35.34%
0.41
アフターアワーズ：
1.65
0.08
+5.10%
Outlook Therapeutics Inc (OTLK) 最新ニュース
Outlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/LYTENAVA™ (bevacizumab-vikg) as a Treatment for Wet AMD - Yahoo Finance Singapore
Outlook Therapeutics Surges As FDA Fast-Tracks ONS-5010 Review - timothysykes.com
Why Outlook Therapeutics (OTLK) Is Up 57.1% After FDA Validates LYTENAVA Efficacy and BLA Resubmission - Yahoo Finance Singapore
OTLK Stock Surges On FDA Lytenava Application Resubmission After Successful Appeal - Stocktwits
OTLK Jumps As Outlook Therapeutics Wins FDA Backing On BLA Resubmission - timothysykes.com
symbol__ Stock Quote Price and Forecast - CNN
OTLK Stock Jumps As FDA Fast-Tracks Lytenava Review - timothysykes.com
OTLK Stock Jumps As FDA Fast-Tracks Lytenava Resubmission - StocksToTrade
OTLK Stock Jumps As FDA Fast-Tracks Lytenava Decision - timothysykes.com
Why Is OTLK Stock Falling Today? - Stocktwits
📈📈📈📈📈📈📈📈📈📈📈📈📈📈📈📈📈📈📈 - Moomoo
OTLK Maintained by Ascendiant Capital -- Price Target Raised to $10.00 - GuruFocus
Outlook Therapeutics Gains as FDA Timeline for Lytenava Comes Up - TechStock²
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
OTLK stock surges over 50% pre-market, breaches key technical milestone – what’s behind this massive rally? - MSN
Outlook Therapeutics gains on FDA appeal win, boosting chances for Lytenava approval. - Pluang
Outlook Therapeutics: Potential Catalysts Offering An Arbitrage Opportunity (NASDAQ:OTLK) - Seeking Alpha
Outlook Therapeutics director Haddadin Yezan Munther buys $24,145 in shares - Investing.com UK
Outlook Therapeutics director Haddadin Yezan Munther buys $24,145 in shares By Investing.com - Investing.com South Africa
Outlook Therapeutics (OTLK) Stock Forum and Discussion - Moomoo
Director at Outlook Therapeutics (NASDAQ: OTLK) buys 29,000 shares - Stock Titan
OTLK stock surges on FDA Lytenava application resubmission after successful appeal - MSN
Outlook Therapeutics Resubmits FDA Application for ONS-5010 - The Globe and Mail
$Outlook Therapeutics (OTLK.US)$ Looking forward to seeing what you can do tonight. - Moomoo
Outlook Therapeutics director’s firm buys $5m in common stock - Investing.com UK
Outlook Therapeutics director’s firm buys $5m in common stock By Investing.com - Investing.com South Africa
GMS Ventures lifts Outlook Therapeutics (OTLK) stake in $5M share deal - Stock Titan
[SCHEDULE 13D/A] Outlook Therapeutics, Inc. Amended Major Shareholder Report - Stock Titan
Outlook Therapeutics resubmits drug application to FDA - Investing.com UK
Outlook resubmits wet AMD BLA for bevacizumab after FDA appeal win - Eyes On Eyecare
Outlook Therapeutics (NASDAQ: OTLK) seeks approval for reverse split and major share increase - Stock Titan
Outlook Therapeutics resubmits drug application to FDA By Investing.com - Investing.com South Africa
Outlook Therapeutics (OTLK) Resubmits Biologics License Applicat - GuruFocus
Outlook Therapeutics, Inc. Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA? (bevacizumab-vikg) - marketscreener.com
Outlook Therapeutics (Nasdaq: OTLK) resubmits FDA BLA with 60-day review - Stock Titan
Outlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg) - The Manila Times
U.S. FDA receives ONS-5010 Biologics License Application from Outlook Therapeutics - Traders Union
Outlook Therapeutics Announces Resubmission of Biologics - GlobeNewswire
1.27%
1.43%
大文字化:
|
ボリューム (24 時間):